SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Mehta, J. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chen, J.
Right arrow Articles by Mehta, J. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Tumor Necrosis Factor-{alpha}-Induced Apoptosis of Human Coronary Artery Endothelial Cells: Modulation by the Peroxisome Proliferator-Activated Receptor-{gamma} Ligand Pioglitazone

Jiawei Chen, MD

Physiology and Biophysics, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas

Dayuan Li, MD, PhD

Xingjian Zhang, MD

Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas

Jawahar L. Mehta, MD, PhD

Physiology and Biophysics, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 West Markham St., Slot 532, Little Rock, AR 72205- 7199; mehtajl{at}uams.edu

The cytokine tumor necrosis factor-a (TNF-{alpha}) plays an important role in endothelial injury, which is associated with the release of reactive oxygen species and the induction of apoptosis. We report on our study of TNF-{alpha}-induced apoptosis in human coronary artery endothelial cells and its modulation by the peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) ligand pioglitazone. Treatment of cells with TNF-{alpha} (40 ng/mL) resulted in apoptosis as measured by DNA laddering and caspase-3 activation. TNF-{alpha} treatment decreased the expression of antiapoptotic protein Bcl-2 (P < .05 vs control), but not the expression of Fas or FLIP, in human coronary artery endothelial cells. Treatment of cells with TNF-{alpha} also enhanced lipid peroxidation (P < .01 vs control). Pretreatment of cells with the PPAR-{gamma} ligand pioglitazone blocked TNF-{alpha}-mediated apoptosis, caspase-3 activation, expression of Bcl-2, and lipid peroxidation (P < .01 vs TNF-{alpha} alone). These results indicate that TNF-{alpha} induces oxidative stress in human coronary artery endothelial cells, resulting in apoptosis through a reduction in Bcl-2 expression and the subsequent activation of caspase-3. The PPAR-{gamma} ligand pioglitazone modulates lipid peroxidation, alters Bcl-2 expression and caspase-3 activation, and finally reduces apoptosis. The antioxidant and antiapoptotic effects of pioglitazone may be the mechanism by which this agent reduces endothelial injury.

Key Words: apoptosis • tumor necrosis factor-{alpha} • peroxisome proliferator-activated receptor-{gamma} • pioglitazone, endothelial cells

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1, 35-41 (2004)
DOI: 10.1177/107424840400900i106


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
M. R. Dasu, S. Park, S. Devaraj, and I. Jialal
Pioglitazone Inhibits Toll-Like Receptor Expression and Activity in Human Monocytes and db/db Mice
Endocrinology, August 1, 2009; 150(8): 3457 - 3464.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
U. Khanderia, R. Pop-Busui, and K. A Eagle
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective
Ann. Pharmacother., October 1, 2008; 42(10): 1466 - 1474.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Migita and J. Morser
15-Deoxy-{Delta}12,14-Prostaglandin J2 (15d-PGJ2) Signals Through Retinoic Acid Receptor-Related Orphan Receptor-{alpha} but Not Peroxisome Proliferator-Activated Receptor-{gamma} in Human Vascular Endothelial Cells: The Effect of 15d-PGJ2 on Tumor Necrosis Factor-{alpha}-Induced Gene Expression
Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 710 - 716.
[Abstract] [Full Text] [PDF]



Advertisement